Changeflow GovPing Healthcare & Life Sciences Patent Application: Therapeutic Compounds - Ore...
Routine Notice Added Draft

Patent Application: Therapeutic Compounds - Orexin-1 Receptor Antagonists

Favicon for changeflow.com USPTO Patent Applications - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO has published a new patent application (US20260085060A1) for therapeutic compounds that act as orexin-1 receptor antagonists. The application, filed on September 25, 2025, details compounds with structural formula (I), their preparation, and pharmaceutical uses.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a published patent application from the USPTO for novel therapeutic compounds identified as orexin-1 receptor antagonists. The application, filed on September 25, 2025, and published as US20260085060A1, describes compounds with a specific structural formula (I), processes for their synthesis, pharmaceutical compositions containing them, and their potential use in treating diseases linked to orexin-1 receptor activity.

This is a patent application, not a final rule or guidance. It does not impose immediate compliance obligations. However, it signals potential future intellectual property rights and market exclusivity for compounds targeting orexin-1 receptors, which may be relevant for pharmaceutical companies and drug manufacturers in their research and development strategies.

Archived snapshot

Mar 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

THERAPEUTIC COMPOUNDS

Application US20260085060A1 Kind: A1 Mar 26, 2026

Inventors

Barrie Phillip Martin

Abstract

The present invention relates to compounds that are antagonists of the orexin-1 receptor. The compounds have the structural formula (I) defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with orexin-1 receptor activity.

CPC Classifications

C07D 401/14

Filing Date

2025-09-25

Application No.

19340185

View original document →

Named provisions

Inventors Abstract CPC Classifications

Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
September 25th, 2025
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260085060A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Development Pharmaceutical Research
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Intellectual Property Drug Development

Get alerts for this source

We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!